Key points from article :
Bit.bio has revealed its early pipeline of regenerative medicine candidates.
The lead cell therapy program, bbHEP01, comprises encapsulated hepatocyte-like cells made using its opti-ox tech.
“We identify the transcription factors that determine particular cells, and we can switch pluripotent stem cells into mature cells with opti-ox,” CEO Mark Kotter.
bbHEP01 is at the preclinical stage for the treatment of acute/acute-on-chronic liver failure, plans to begin Phase I in 2025.
Bit.bio's pipeline also includes cell therapies comprising pancreatic islet cells, GABAergic neurons and myeloid & natural killer cells.
Raised $41.5 million in a Series A round in 2020, followed by a $103 million Series B in 2021.
Bit.bio is also interested in extending healthspan by 20 years through DNA research.
